Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trialOrnella Verrastro, Geltrude Mingrone, Francesco Pennestrì et al.|The Lancet|2023Cited by 338
Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetesErminia Lembo, Esmeralda Capristo, Maria Francesca Russo et al.|Diabetes & Metabolism|2022Cited by 22
Personalizing bariatric metabolic surgery: Predictors of weight-loss success and risk of weight recurrenceSimona Panunzi, Geltrude Mingrone, Sara Russo et al.|Metabolism|2026Cited by 2
WED-215 HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooningGiulia Angelini, Geltrude Mingrone, Sara Russo et al.|Journal of Hepatology|2024Cited by 0